Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SLO-PHYLLIN vs ELIXICON
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.
Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma and other chronic lung diseases (e.g., COPD, emphysema, chronic bronchitis),Off-label: Apnea of prematurity,Off-label: Adjunctive therapy in acute asthma exacerbations (rarely used)
Treatment of symptoms and reversible airflow obstruction associated with chronic asthma,Management of chronic obstructive pulmonary disease (COPD),Off-label: Apnea of prematurity
Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.
400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.
Terminal elimination half-life is approximately 3-8 hours in adults (non-smokers, healthy), 1-5 hours in smokers, and 20-30 hours in neonates. Clinical context: Half-life is prolonged in hepatic cirrhosis, heart failure, and with certain drug interactions (e.g., cimetidine, ciprofloxacin).
Terminal elimination half-life: 4-6 hours in adults; 3-4 hours in children; prolonged in hepatic impairment or congestive heart failure. Context: dosing interval adjustment required in these conditions.
Primarily hepatic via CYP450 enzymes: CYP1A2, CYP2E1, CYP3A4; metabolite: 1,3-dimethyluric acid. Approximately 10% excreted unchanged in urine.
Primarily hepatic metabolism via cytochrome P450 1A2 (CYP1A2). Minor pathways include CYP2E1 and CYP3A4. Metabolites are excreted renally.
Renal: ~10% unchanged; hepatic metabolism accounts for ~90% of elimination, with metabolites excreted in urine. Fecal: <5%.
Renal: 50% unchanged; hepatic metabolism to 3-methylxanthine, theophylline, etc. Biliary/fecal: minimal.
Approximately 40% bound to albumin; binding is saturable and decreased in neonates, hepatic disease, and acidosis.
Approximately 40% bound, primarily to albumin.
0.45 L/kg (range 0.3-0.7 L/kg). Clinical meaning: Distributes evenly into body water and highly perfused tissues; Vd increased in premature infants and decreased in obesity.
Vd: 0.3-0.5 L/kg; indicates distribution into total body water, minimal tissue binding.
Oral immediate-release: 96-100%; oral sustained-release (Slo-Phyllin): 90-100% relative to immediate-release; rectal: variable (~80-100% for enema); IV: 100%.
Oral immediate-release: 100%; Extended-release: 100% (well-absorbed, no first-pass metabolism).
No specific dose adjustment is required for renal impairment. However, monitoring serum concentrations is recommended due to altered clearance in severe renal failure (GFR <10 m L/min).
GFR > 50 m L/min: no adjustment; GFR 10-50 m L/min: reduce dose by 25-50% and monitor theophylline levels; GFR < 10 m L/min: reduce dose by 50% and monitor levels.
Child-Pugh Class B or C: Reduce dose by 50% and monitor serum concentrations closely. Avoid use in severe hepatic impairment if possible.
Child-Pugh Class A: no adjustment; Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: reduce dose by 75% and monitor levels.
Starting dose: 5 mg/kg/day orally in divided doses every 6 hours (immediate-release) or every 12 hours (sustained-release). Titrate based on serum concentrations, targeting 5-15 mcg/m L. Maximum dose: 24 mg/kg/day or 900 mg/day, whichever is less.
Initial: 5 mg/kg/dose orally every 6 hours; maintenance: 100-400 mg/day in divided doses; monitor levels aggressively.
Start at low end of dosing range (e.g., 200-300 mg/day sustained-release). Monitor serum concentrations carefully as clearance is reduced in elderly patients, increasing risk of toxicity.
Start at lowest effective dose (e.g., 200 mg orally every 12 hours) due to reduced clearance; monitor theophylline levels and adjust based on response and tolerability.
No FDA boxed warning.
Theophylline has a narrow therapeutic index; plasma levels should be monitored to avoid toxicity. Dosage should be individualized based on steady-state serum concentrations. Concurrent illness, fever, or changes in smoking habits can alter theophylline clearance.
Concurrent illness (fever, influenza), hepatic impairment, elderly, and smoking alter metabolism; narrow therapeutic index (10-20 mcg/m L); monitor serum levels; risk of seizures, arrhythmias, and death with toxicity; reduce dose with CYP1A2 inhibitors (cimetidine, fluoroquinolones, macrolides) or inducers (smoking, rifampin, phenytoin); caution in peptic ulcer disease, seizure disorders, cardiac arrhythmias.
Risk of seizures at high serum levels; may induce or worsen arrhythmias; use with caution in patients with peptic ulcer disease, hyperthyroidism, or seizure disorders; drug interactions with cimetidine, fluoroquinolones, macrolides, and allopurinol can increase theophylline levels.
Hypersensitivity to theophylline or any component,Pre-existing arrhythmia (especially tachyarrhythmias),Active seizure disorder not adequately controlled
Hypersensitivity to theophylline or any component of the formulation; pre-existing cardiac arrhythmias (e.g., tachyarrhythmias); active seizure disorder.
Avoid high-fat meals as they may alter absorption of sustained-release preparations. Limit caffeine-containing foods and beverages. Avoid charcoal-broiled foods, which can increase metabolism.
Avoid large amounts of caffeine-containing foods and beverages such as coffee, tea, cola, and chocolate as they may increase side effects like jitteriness and insomnia. High-fat meals may affect absorption; take consistently with respect to meals. Charcoal-broiled foods may increase metabolism of theophylline, reducing efficacy.
Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester exposure is not associated with major congenital malformations. Third trimester use may lead to transient neonatal apnea, jitteriness, or tachycardia due to placental transfer. No increased risk of preterm birth or low birth weight has been consistently demonstrated.
Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly needed.
Theophylline is excreted into breast milk with an M/P ratio of approximately 0.7. Infant serum levels can reach therapeutic concentrations if maternal doses are high. Breastfeeding is generally considered compatible, but monitor the infant for signs of theophylline toxicity (e.g., irritability, insomnia, tachycardia).
Excreted into breast milk; M/P ratio unknown. Caution advised, monitor infant for adverse effects.
Pregnancy may decrease theophylline clearance by 20-30%, particularly in the third trimester, due to reduced hepatic metabolism. Dose adjustments may be needed to maintain therapeutic levels. Postpartum, clearance returns to prepregnancy levels within 4-6 weeks; reduce dose accordingly to avoid toxicity.
Increased clearance during pregnancy may require dose adjustment; monitor therapeutic levels.
Monitor serum theophylline levels closely due to narrow therapeutic index (10-20 mcg/m L). Adjust dose in patients with heart failure, liver disease, or on CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine). Do not crush or chew sustained-release tablets. Cigarette smoking induces metabolism, requiring higher doses.
ELIXICON (theophylline) requires therapeutic drug monitoring due to narrow therapeutic index of 10-20 mcg/m L. Avoid in patients with active peptic ulcer disease or seizure disorders. Use with caution in heart failure, liver disease, and elderly patients due to reduced clearance. Cigarette smoking induces metabolism, requiring dose adjustments. Common side effects include nausea, vomiting, and insomnia; toxicity presents with tachycardia, seizures, or ventricular arrhythmias.
Take this medication exactly as prescribed, usually every 8-12 hours.,Do not crush or chew the tablets; swallow them whole.,Avoid excessive caffeine intake (coffee, tea, chocolate) as it may increase side effects.,Contact your doctor if you experience nausea, vomiting, insomnia, or irregular heartbeat.,Do not change brands or formulations without consulting your doctor.
Take exactly as prescribed and do not change dose without consulting your doctor.,Avoid smoking and second-hand smoke as it affects how the medication works.,Limit caffeine intake (coffee, tea, chocolate, cola) as it may increase side effects.,Report symptoms of toxicity: persistent nausea, vomiting, rapid heart rate, or seizures.,Do not take this medication with other cold or asthma remedies without medical advice.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SLO-PHYLLIN vs ELIXICON, answered by our medical review team.
SLO-PHYLLIN is a Xanthine Bronchodilator that works by SLO-PHYLLIN (theophylline) is a xanthine bronchodilator that relaxes bronchial smooth muscle, likely by inhibiting phosphodiesterase, increasing intracellular c AMP, blocking adenosine receptors, and enhancing endogenous catecholamine release.. ELIXICON is a Xanthine Bronchodilator that works by Theophylline is a xanthine derivative that inhibits phosphodiesterase, leading to increased intracellular cyclic AMP levels. It also acts as a nonselective adenosine receptor antagonist, resulting in bronchodilation and anti-inflammatory effects.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SLO-PHYLLIN and ELIXICON depend on the specific clinical indication. These are both Xanthine Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SLO-PHYLLIN is: Theophylline (Slo-Phyllin) immediate-release: 100-200 mg orally every 6 hours; sustained-release: 200-400 mg orally every 12 hours. Dose titrated to serum theophylline concentration of 5-15 mcg/m L.. The standard adult dose of ELIXICON is: 400 mg orally every 6 hours or 600 mg orally every 8 hours; extended-release: 600-1200 mg orally every 12 hours.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SLO-PHYLLIN and ELIXICON in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SLO-PHYLLIN is classified as Category C. Theophylline (Slo-Phyllin) is classified as FDA Pregnancy Category C. Animal studies have shown teratogenic effects at high doses, but human data are limited. First trimester expos. ELIXICON is classified as Category C. Insufficient human data; animal studies show fetal toxicity at high doses. Avoid in first trimester unless benefit outweighs risk. Second and third trimester: use only if clearly n. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.